Does the media prefer ENLV or ACRS?

In the previous week, Enlivex Therapeutics and Enlivex Therapeutics both had 2 articles in the media. Enlivex Therapeutics' average media sentiment score of 0.62 equaled Aclaris Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enlivex Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aclaris Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ENLV or TLRY?

In the previous week, Tilray Brands had 22 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 24 mentions for Tilray Brands and 2 mentions for Enlivex Therapeutics. Tilray Brands' average media sentiment score of 0.68 beat Enlivex Therapeutics' score of 0.62 indicating that Tilray Brands is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enlivex Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tilray Brands 9 Very Positive mention(s) 4 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, DRUG or ENLV?

Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bright Minds Biosciences N/A N/A -$8.74M -$2.44 N/A Enlivex Therapeutics N/A N/A $1.24B -$0.55 N/A

Is DRUG or ENLV more profitable?

Enlivex Therapeutics' return on equity of 248.08% beat Bright Minds Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Bright Minds Biosciences N/A -20.58% -20.25% Enlivex Therapeutics N/A 248.08% 206.39%

Which has better valuation & earnings, ENLV or TECX?

Tectonic Therapeutic is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Enlivex Therapeutics N/A N/A $1.24B -$0.55 N/A Tectonic Therapeutic N/A N/A -$74.15M -$4.46 N/A

Is ENLV or TECX more profitable?

Enlivex Therapeutics' return on equity of 248.08% beat Tectonic Therapeutic's return on equity. Company Net Margins Return on Equity Return on Assets Enlivex Therapeutics N/A 248.08% 206.39% Tectonic Therapeutic N/A -32.33% -30.92%

Enlivex Therapeutics (ENLV) Competitors

$0.58 +0.01 (+1.75%)

Closing price 04:00 PM Eastern

Extended Trading

$0.62 +0.04 (+6.03%)

As of 07:57 PM Eastern

Compare

ENLV vs. ACRS, TLRY, DRUG, GYRE, and TECX

Should you buy Enlivex Therapeutics stock or one of its competitors? MarketBeat compares Enlivex Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Enlivex Therapeutics include Aclaris Therapeutics (ACRS), Tilray Brands (TLRY), Bright Minds Biosciences (DRUG), Gyre Therapeutics (GYRE), and Tectonic Therapeutic (TECX). These companies are all part of the "pharmaceutical products" industry.

How does Enlivex Therapeutics compare to Aclaris Therapeutics?

Enlivex Therapeutics (NASDAQ:ENLV) and Aclaris Therapeutics (NASDAQ:ACRS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, dividends, analyst recommendations, earnings and valuation.

Enlivex Therapeutics has a beta of 1.47, indicating that its share price is 47% more volatile than the broader market. Comparatively, Aclaris Therapeutics has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market.

Enlivex Therapeutics has higher earnings, but lower revenue than Aclaris Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enlivex Therapeutics	N/A	N/A	$1.24B	-$0.55	N/A
Aclaris Therapeutics	$7.83M	89.54	-$64.92M	-$0.56	N/A

In the previous week, Enlivex Therapeutics and Enlivex Therapeutics both had 2 articles in the media. Enlivex Therapeutics' average media sentiment score of 0.62 equaled Aclaris Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enlivex Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aclaris Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Enlivex Therapeutics presently has a consensus price target of $16.50, indicating a potential upside of 2,744.83%. Aclaris Therapeutics has a consensus price target of $11.50, indicating a potential upside of 129.08%. Given Enlivex Therapeutics' higher probable upside, equities analysts clearly believe Enlivex Therapeutics is more favorable than Aclaris Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enlivex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13

1.0% of Enlivex Therapeutics shares are held by institutional investors. Comparatively, 98.3% of Aclaris Therapeutics shares are held by institutional investors. 12.3% of Enlivex Therapeutics shares are held by company insiders. Comparatively, 4.8% of Aclaris Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Enlivex Therapeutics has a net margin of 0.00% compared to Aclaris Therapeutics' net margin of -832.58%. Enlivex Therapeutics' return on equity of 248.08% beat Aclaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enlivex Therapeutics	N/A	248.08%	206.39%
Aclaris Therapeutics	-832.58%	-55.89%	-38.49%

Summary

Enlivex Therapeutics beats Aclaris Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Enlivex Therapeutics compare to Tilray Brands?

Enlivex Therapeutics (NASDAQ:ENLV) and Tilray Brands (NASDAQ:TLRY) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation, institutional ownership and media sentiment.

Enlivex Therapeutics has a net margin of 0.00% compared to Tilray Brands' net margin of -156.51%. Enlivex Therapeutics' return on equity of 248.08% beat Tilray Brands' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enlivex Therapeutics	N/A	248.08%	206.39%
Tilray Brands	-156.51%	-3.31%	-2.42%

Enlivex Therapeutics has higher earnings, but lower revenue than Tilray Brands. Enlivex Therapeutics is trading at a lower price-to-earnings ratio than Tilray Brands, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enlivex Therapeutics	N/A	N/A	$1.24B	-$0.55	N/A
Tilray Brands	$821.31M	0.65	-$2.19B	-$13.65	N/A

Enlivex Therapeutics currently has a consensus target price of $16.50, suggesting a potential upside of 2,744.83%. Tilray Brands has a consensus target price of $11.50, suggesting a potential upside of 149.46%. Given Enlivex Therapeutics' higher probable upside, research analysts plainly believe Enlivex Therapeutics is more favorable than Tilray Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enlivex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Tilray Brands	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25

1.0% of Enlivex Therapeutics shares are held by institutional investors. Comparatively, 9.4% of Tilray Brands shares are held by institutional investors. 12.3% of Enlivex Therapeutics shares are held by insiders. Comparatively, 0.8% of Tilray Brands shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Tilray Brands had 22 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 24 mentions for Tilray Brands and 2 mentions for Enlivex Therapeutics. Tilray Brands' average media sentiment score of 0.68 beat Enlivex Therapeutics' score of 0.62 indicating that Tilray Brands is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enlivex Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tilray Brands	9 Very Positive mention(s)	4 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Enlivex Therapeutics has a beta of 1.47, meaning that its share price is 47% more volatile than the broader market. Comparatively, Tilray Brands has a beta of 1.88, meaning that its share price is 88% more volatile than the broader market.

Summary

Enlivex Therapeutics and Tilray Brands tied by winning 7 of the 14 factors compared between the two stocks.

How does Enlivex Therapeutics compare to Bright Minds Biosciences?

Bright Minds Biosciences (NASDAQ:DRUG) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, institutional ownership, media sentiment and profitability.

In the previous week, Enlivex Therapeutics had 1 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 2 mentions for Enlivex Therapeutics and 1 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 1.90 beat Enlivex Therapeutics' score of 0.62 indicating that Bright Minds Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Bright Minds Biosciences	Very Positive
Enlivex Therapeutics	Positive

Bright Minds Biosciences has a beta of -5.53, indicating that its stock price is 653% less volatile than the broader market. Comparatively, Enlivex Therapeutics has a beta of 1.47, indicating that its stock price is 47% more volatile than the broader market.

Enlivex Therapeutics' return on equity of 248.08% beat Bright Minds Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bright Minds Biosciences	N/A	-20.58%	-20.25%
Enlivex Therapeutics	N/A	248.08%	206.39%

Bright Minds Biosciences presently has a consensus price target of $143.83, suggesting a potential upside of 107.91%. Enlivex Therapeutics has a consensus price target of $16.50, suggesting a potential upside of 2,744.83%. Given Enlivex Therapeutics' higher possible upside, analysts plainly believe Enlivex Therapeutics is more favorable than Bright Minds Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bright Minds Biosciences	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
Enlivex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

40.5% of Bright Minds Biosciences shares are held by institutional investors. Comparatively, 1.0% of Enlivex Therapeutics shares are held by institutional investors. 42.7% of Bright Minds Biosciences shares are held by insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$2.44	N/A
Enlivex Therapeutics	N/A	N/A	$1.24B	-$0.55	N/A

Summary

Enlivex Therapeutics beats Bright Minds Biosciences on 7 of the 12 factors compared between the two stocks.

How does Enlivex Therapeutics compare to Gyre Therapeutics?

Enlivex Therapeutics (NASDAQ:ENLV) and Gyre Therapeutics (NASDAQ:GYRE) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment.

In the previous week, Enlivex Therapeutics had 1 more articles in the media than Gyre Therapeutics. MarketBeat recorded 2 mentions for Enlivex Therapeutics and 1 mentions for Gyre Therapeutics. Gyre Therapeutics' average media sentiment score of 1.87 beat Enlivex Therapeutics' score of 0.62 indicating that Gyre Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Enlivex Therapeutics	Positive
Gyre Therapeutics	Very Positive

Enlivex Therapeutics has higher earnings, but lower revenue than Gyre Therapeutics. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enlivex Therapeutics	N/A	N/A	$1.24B	-$0.55	N/A
Gyre Therapeutics	$116.59M	6.17	$5.03M	-$0.09	N/A

Enlivex Therapeutics presently has a consensus price target of $16.50, indicating a potential upside of 2,744.83%. Gyre Therapeutics has a consensus price target of $17.00, indicating a potential upside of 163.57%. Given Enlivex Therapeutics' higher probable upside, equities analysts clearly believe Enlivex Therapeutics is more favorable than Gyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enlivex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Gyre Therapeutics	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Enlivex Therapeutics has a net margin of 0.00% compared to Gyre Therapeutics' net margin of -5.44%. Enlivex Therapeutics' return on equity of 248.08% beat Gyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enlivex Therapeutics	N/A	248.08%	206.39%
Gyre Therapeutics	-5.44%	3.13%	2.67%

1.0% of Enlivex Therapeutics shares are held by institutional investors. Comparatively, 24.0% of Gyre Therapeutics shares are held by institutional investors. 12.3% of Enlivex Therapeutics shares are held by insiders. Comparatively, 9.5% of Gyre Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Enlivex Therapeutics has a beta of 1.47, meaning that its share price is 47% more volatile than the broader market. Comparatively, Gyre Therapeutics has a beta of 1.91, meaning that its share price is 91% more volatile than the broader market.

Summary

Enlivex Therapeutics beats Gyre Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Enlivex Therapeutics compare to Tectonic Therapeutic?

Enlivex Therapeutics (NASDAQ:ENLV) and Tectonic Therapeutic (NASDAQ:TECX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

Enlivex Therapeutics has a beta of 1.47, indicating that its share price is 47% more volatile than the broader market. Comparatively, Tectonic Therapeutic has a beta of 3.19, indicating that its share price is 219% more volatile than the broader market.

1.0% of Enlivex Therapeutics shares are owned by institutional investors. Comparatively, 62.6% of Tectonic Therapeutic shares are owned by institutional investors. 12.3% of Enlivex Therapeutics shares are owned by insiders. Comparatively, 39.8% of Tectonic Therapeutic shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Enlivex Therapeutics' return on equity of 248.08% beat Tectonic Therapeutic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enlivex Therapeutics	N/A	248.08%	206.39%
Tectonic Therapeutic	N/A	-32.33%	-30.92%

Tectonic Therapeutic is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enlivex Therapeutics	N/A	N/A	$1.24B	-$0.55	N/A
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.46	N/A

Enlivex Therapeutics presently has a consensus target price of $16.50, indicating a potential upside of 2,744.83%. Tectonic Therapeutic has a consensus target price of $79.40, indicating a potential upside of 139.95%. Given Enlivex Therapeutics' higher possible upside, equities analysts plainly believe Enlivex Therapeutics is more favorable than Tectonic Therapeutic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enlivex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Tectonic Therapeutic	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Enlivex Therapeutics had 1 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 2 mentions for Enlivex Therapeutics and 1 mentions for Tectonic Therapeutic. Tectonic Therapeutic's average media sentiment score of 1.87 beat Enlivex Therapeutics' score of 0.62 indicating that Tectonic Therapeutic is being referred to more favorably in the news media.

Company	Overall Sentiment
Enlivex Therapeutics	Positive
Tectonic Therapeutic	Very Positive

Summary

Tectonic Therapeutic beats Enlivex Therapeutics on 7 of the 13 factors compared between the two stocks.

Get Enlivex Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENLV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ENLV vs. The Competition

Export

Metric	Enlivex Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$135.31M	$3.06B	$6.84B	$12.43B
Dividend Yield	N/A	1.87%	2.67%	6.11%
P/E Ratio	N/A	19.67	25.83	24.36
Price / Sales	N/A	358.40	511.51	84.16
Price / Cash	N/A	56.85	29.09	36.93
Price / Book	0.07	4.25	10.98	6.49
Net Income	$1.24B	$64.45M	$3.57B	$336.61M
7 Day Performance	-6.90%	4.17%	3.06%	0.90%
1 Month Performance	-28.42%	1.44%	0.72%	-0.36%
1 Year Performance	-51.67%	34.07%	36.82%	31.26%

Enlivex Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ENLV Enlivex Therapeutics	3.115 of 5 stars	$0.58 +1.8%	$16.50 +2,744.8%	-52.5%	$135.31M	N/A	N/A	70
ACRS Aclaris Therapeutics	3.1058 of 5 stars	$4.34 -0.5%	$11.50 +165.0%	+240.1%	$608.93M	$7.83M	N/A	100
TLRY Tilray Brands	2.8571 of 5 stars	$4.88 -2.6%	$11.50 +135.7%	+15.8%	$583.91M	$821.31M	N/A	2,842
DRUG Bright Minds Biosciences	3.0633 of 5 stars	$59.82 +1.1%	$143.83 +140.4%	+182.7%	$575.85M	N/A	N/A	N/A	Positive News
GYRE Gyre Therapeutics	2.1682 of 5 stars	$5.82 -0.7%	$17.00 +192.1%	-14.7%	$568.59M	$116.59M	N/A	40	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ENLV) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Enlivex Therapeutics (ENLV) Competitors

ENLV vs. ACRS, TLRY, DRUG, GYRE, and TECX

How does Enlivex Therapeutics compare to Aclaris Therapeutics?

Summary

How does Enlivex Therapeutics compare to Tilray Brands?

Summary

How does Enlivex Therapeutics compare to Bright Minds Biosciences?

Summary

How does Enlivex Therapeutics compare to Gyre Therapeutics?

Summary

How does Enlivex Therapeutics compare to Tectonic Therapeutic?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENLV vs. The Competition

Enlivex Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Enlivex Therapeutics (ENLV) Competitors

ENLV vs. ACRS, TLRY, DRUG, GYRE, and TECX

How does Enlivex Therapeutics compare to Aclaris Therapeutics?

Which has more volatility and risk, ENLV or ACRS?

Which has better earnings & valuation, ENLV or ACRS?

Does the media prefer ENLV or ACRS?

Do analysts recommend ENLV or ACRS?

Do insiders & institutionals believe in ENLV or ACRS?

Is ENLV or ACRS more profitable?

Summary

How does Enlivex Therapeutics compare to Tilray Brands?

Is ENLV or TLRY more profitable?

Which has stronger earnings and valuation, ENLV or TLRY?

Do analysts rate ENLV or TLRY?

Do insiders and institutionals hold more shares of ENLV or TLRY?

Does the media favor ENLV or TLRY?

Which has more volatility and risk, ENLV or TLRY?

Summary

How does Enlivex Therapeutics compare to Bright Minds Biosciences?

Does the media favor DRUG or ENLV?

Which has more volatility & risk, DRUG or ENLV?

Is DRUG or ENLV more profitable?

Do analysts rate DRUG or ENLV?

Do institutionals and insiders hold more shares of DRUG or ENLV?

Which has higher valuation & earnings, DRUG or ENLV?

Summary

How does Enlivex Therapeutics compare to Gyre Therapeutics?

Does the media prefer ENLV or GYRE?

Which has preferable valuation & earnings, ENLV or GYRE?

Do analysts recommend ENLV or GYRE?

Is ENLV or GYRE more profitable?

Do institutionals and insiders believe in ENLV or GYRE?

Which has more volatility & risk, ENLV or GYRE?

Summary

How does Enlivex Therapeutics compare to Tectonic Therapeutic?

Which has more risk and volatility, ENLV or TECX?

Do institutionals and insiders believe in ENLV or TECX?

Is ENLV or TECX more profitable?

Which has better valuation & earnings, ENLV or TECX?

Do analysts prefer ENLV or TECX?

Does the media prefer ENLV or TECX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENLV vs. The Competition

Enlivex Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools